← back to search

Patrizia Mondello

Mayo Clinic · US
Area of research
Pathology and Forensic Medicine · Organic Chemistry
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Quinazolinone synthesis and applications, and Synthesis and biological activity.
h-index
27
citations
2,343
works
305
NIH funding
primary concept
email

Recent publications

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
Annals of Hematology 2023cited by 21position: middledoi
POSTER: ABCL-673 Single Cell Analysis Reveals Immune Dysfunction in Large B-Cell Lymphoma (LBCL) Patients With Hypomagnesemia Receiving Axi-Cel: Results from ZUMA-1 Trial and Mayo Clinic Cohort
Clinical Lymphoma Myeloma & Leukemia 2023cited by 0position: firstdoi
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
Clinical Cancer Research 2022cited by 27position: middledoi
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
Blood Cancer Journal 2021cited by 66position: middledoi
Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma
Blood Cancer Journal 2021cited by 65position: firstdoi
Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Blood 2021cited by 8position: middledoi
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma
Cancer Discovery 2020cited by 158position: firstdoi
Frontline treatment of diffuse large B‐cell lymphoma: Beyond R‐CHOP
Hematological Oncology 2019cited by 56position: firstdoi
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
Cancer Immunology Research 2016cited by 175position: middledoi
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study
Annals of Hematology 2016cited by 33position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Grzegorz S. Nowakowski · Mayo Clinic4 papers (2021–2023)Gilles Salles · Universidade Federal do Estado do Rio de Janeiro4 papers (2021–2023)Erel Joffe · Kettering University4 papers (2021–2023) · 3 papers (2021–2023) · 3 papers (2021–2023) · 3 papers (2021–2023)Matthew Ku · City of Hope3 papers (2021–2023)Judith Trotman · Repatriation General Hospital3 papers (2021–2023)Reinhard Marks · Northwell Health3 papers (2021–2023)Pier Luigi Zinzani · Marche Polytechnic University3 papers (2021–2023)Kibum Kim · University of Utah3 papers (2021–2023)Isabelle Fleury · Hôpital Maisonneuve-Rosemont3 papers (2021–2023)Georg Heß · Johannes Gutenberg University Mainz3 papers (2021–2023)Dok Hyun Yoon · Sungkyunkwan University3 papers (2021–2023)Richard Greil · EB House Austria3 papers (2021–2023) · 3 papers (2021–2023)Michael Mian · University of Arkansas for Medical Sciences2 papers (2016–2019) · 2 papers (2021–2023)Raúl Córdoba · Hospital Universitario Fundación Jiménez Díaz2 papers (2021–2023)Dan Huang · Fudan University2 papers (2021–2022)